Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults (EXSFN)
19 de junho de 2026 atualizado por: Hashim Islam, University of British Columbia
Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults: A Randomized Crossover Study
The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion.
The interventional periods will be separated by a minimum 1 week washout period.
One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite).
Another intervention will consist of 4 days of daily supervised treadmill running.
The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions.
The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training.
Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected.
Blood samples will be analyzed for metabolic and inflammatory markers.
Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods.
Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires.
The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.
Visão geral do estudo
Status
Recrutamento
Tipo de estudo
Intervencional
Inscrição (Estimado)
20
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Hashim Islam Principle Investigator, Ph.D
- Número de telefone: 250-807-9122
- E-mail: hashim.islam@ubc.ca
Locais de estudo
-
-
British Columbia
-
Kelowna, British Columbia, Canadá, V1V 1V7
- Recrutamento
- Reichwald Health Sciences Centre
-
Contato:
- Sean McIntyre
- Número de telefone: 2505757528
- E-mail: smcint04@student.ubc.ca
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Sim
Descrição
Inclusion Criteria:
- aged between 18 and 35 years
- not a current smoker
- physically active based on the Canadian Physical Activity Guidelines (150 minutes of weekly physical activity)
Exclusion Criteria:
- a history of cardiometabolic diseases or respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, diabetes, coronary artery disease)
- currently following a ketogenic diet
- body mass index (BMI) over 30 kg/m2
- unable to read or communicate in English
- having received a vaccination or experienced an upper respiratory tract infection in the last 4 weeks
- having donated more than 0.5 L of blood within the last 4 weeks
- currently pregnant
- have contraindications to high intensity exercise (assessed using the CSEP Get Active Questionnaire)
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Ciência básica
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Sulforaphane Supplementation Only
In this intervention, participants will consume commercially available broccoli sprout extract capsules daily for 4 days (20 mg/day) .
Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
|
Broc Elite Plus stabilized sulforaphane capsules from Mara Labs
|
|
Comparador Ativo: Exercise Only
In this intervention, participants will complete supervised exercise sessions daily for 4 days.
The exercise intervention consists of interval running on a treadmill which contains 4 cycles of: 4 minutes of intense running (85-95% HRmax) followed by 3 minutes at a slow, easy pace.
Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
|
4 cycles of: 4 minutes of intense treadmill running (85-95% HR max) followed by 3 minutes of slow, easy running.
|
|
Experimental: Sulforaphane Supplementation and Exercise
In this intervention, participants will consume commercially available broccoli sprout extract tablets daily for 4 days.
In addition, participants will complete supervised exercise sessions daily for 4 days.
The exercise intervention consists of interval running on a treadmill which contains 4 cycles of: 4 minutes of intense running (85-95% HRmax) followed by 3 minutes at a slow, easy pace.
Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
|
Broc Elite Plus stabilized sulforaphane capsules from Mara Labs
4 cycles of: 4 minutes of intense treadmill running (85-95% HR max) followed by 3 minutes of slow, easy running.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in peripheral blood mononuclear cell oxygen consumption rate
Prazo: 0-4 days
|
OCR will be measured using a Seahorse Analyzer before and after each 4-day intervention
|
0-4 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
TNF-alpha secretion from LPS-stimulated whole blood
Prazo: 0-4 days
|
TNF-alpha secretion from LPS-stimulated whole blood will be measured via ELISA before and after each 4-day period
|
0-4 days
|
|
Change in % of classical monocytes before and after the 6-week intervention
Prazo: 0-4 days
|
The % of classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in % of intermediate monocytes before and after the 4-day intervention
Prazo: 0-4 days
|
The % of intermediate monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in % of non-classical monocytes before and after the 4-day intervention
Prazo: 0-4 days
|
The % of non-classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in TLR-4 expression on classical monocytes before and after the 4-day intervention
Prazo: 0-4 days
|
TLR-4 expression on classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention.
|
0-4 days
|
|
Change in TLR-4 expression on intermediate monocytes before and after the 4-day intervention
Prazo: 0-4 days
|
TLR-4 expression on intermediate monocytes will be measured using flow cytometry at baseline and after the 4-day intervention.
|
0-4 days
|
|
Change in TLR-4 expression on non-classical monocytes before and after the 4-day intervention
Prazo: 0-4 days
|
TLR-4 expression on non-classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in white blood cell counts before and after the 4-day intervention
Prazo: 0-4 days
|
White blood cell counts will be measured using a hematology analyzer at baseline and after the 4-day intervention
|
0-4 days
|
|
TNF-alpha secretion from PolyIC-stimulated whole blood
Prazo: 0-4 days
|
TNF-alpha secretion from PolyIC-stimulated whole blood will be measured via ELISA before and after each 4-day period
|
0-4 days
|
|
Change in peripheral blood mononuclear cell extracellular acidification rate before and after the 4-day period
Prazo: 0-4 days
|
PBMC ECAR will be measured using a Seahorse Analyzer at baseline and after the 4-day intervention
|
0-4 days
|
|
Change in PBMC mitotracker green staining before and after the 4-day period
Prazo: 0-4 days
|
PBMC mitotracker green will be measured using flow cytometry before and after the 4-day intervention period
|
0-4 days
|
|
Change in PBMC mitoSOX red staining before and after the 4-day period
Prazo: 0-4 days
|
PBMC mitoSOX red will be measured using flow cytometry before and after the 4-day intervention period
|
0-4 days
|
|
Change in PBMC mitochondrial respiration before and after the 4-day intervention period
Prazo: 0-4 days
|
PBMC mitochondrial respiration will be measured using high-resolution respirometry before and after the 4-day period
|
0-4 days
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de março de 2026
Conclusão Primária (Estimado)
1 de dezembro de 2027
Conclusão do estudo (Estimado)
1 de junho de 2028
Datas de inscrição no estudo
Enviado pela primeira vez
19 de junho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
19 de junho de 2026
Primeira postagem (Real)
25 de junho de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
25 de junho de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
19 de junho de 2026
Última verificação
1 de junho de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- H25-03273
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Descrição do plano IPD
IPD will not be shared to ensure the privacy and confidentiality of participants, in accordance with ethical guidelines and data protection regulations.
Additionally, this was not included in the informed consent, which did not cover data sharing or address potential risks of re-identification.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .